Business News • PR NewsWire • Sanofi's Lyxumia® (lixisenatide) Statistically Superior to Rapid Acting Insulin for Body Weight Change with Similar Blood Sugar Control when Both are Added to Basal Insulin

Sanofi's Lyxumia® (lixisenatide) Statistically Superior to Rapid Acting Insulin for Body Weight Change with Similar Blood Sugar Control when Both are Added to Basal Insulin

Sanofi's Lyxumia® (lixisenatide) Statistically Superior to Rapid Acting Insulin for Body Weight Change with Similar Blood Sugar Control when Both are Added to Basal Insulin

PARIS, June 6, 2015 /PRNewswire-USNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that Lyxumia® (lixisenatide) met all co-primary endpoints in a clinical trial (GetGoal Duo-2) comparing its use as a once-daily add-on to basal insulin versus the addition of...

View More : http://www.prnewswire.com/news-releases/sanofis-lyxumia-lixisenatide-statistically-superior-to-rapid-acting-insulin-for-...

Releted News by prnewswire

Disruption in Access to Diabetes Monitoring Supplies Leads to Increased Hospitalizations, Mortality Among Medicare Beneficiaries

VeroScience Continues Clinical Evaluation of Bromocriptine-QR (Cycloset) and Neurophysiological Investigations of Brain Dopamine Regulation of Metabolism with Eight Papers Presented at the 2015 American Diabetes Association Conference

Mohed Altrad of Altrad Group from France named EY World Entrepreneur Of The Year 2015